{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:28:12Z","timestamp":1785878892685,"version":"3.56.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40259-025-00711-7","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:11:24Z","timestamp":1743898284000},"page":"359-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs"],"prefix":"10.1007","volume":"39","author":[{"given":"Mona","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Hossaini Alhashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dehshahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-41199-1_1","volume":"219","author":"EV Gurevich","year":"2014","unstructured":"Gurevich EV, Gurevich VV. Therapeutic potential of small molecules and engineered proteins. Handb Exp Pharmacol. 2014;219:1\u201312.","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"711_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14712598.2017.1273344","volume":"17","author":"J Tushir-Singh","year":"2017","unstructured":"Tushir-Singh J. Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opin Biol Th. 2017;17(3):325\u201338.","journal-title":"Expert Opin Biol Th"},{"key":"711_CR3","doi-asserted-by":"crossref","unstructured":"Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for treatment of HIV-1 infection. Genome Med. 2015;7.","DOI":"10.1186\/s13073-015-0174-y"},{"issue":"12","key":"711_CR4","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","volume":"40","author":"G Walsh","year":"2022","unstructured":"Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722\u201360.","journal-title":"Nat Biotechnol"},{"key":"711_CR5","doi-asserted-by":"crossref","unstructured":"Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010;9.","DOI":"10.1186\/1476-4598-9-75"},{"issue":"10","key":"711_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673\u201394.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"711_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","volume":"41","author":"N Dammes","year":"2020","unstructured":"Dammes N, Peer D. Paving the road for RNA therapeutics. Trends Pharmacol Sci. 2020;41(10):755\u201375.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"711_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41565-021-00937-w","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics (vol 16, pg 630, 2021). Nat Nanotechnol. 2021;16(7):841.","journal-title":"Nat Nanotechnol"},{"issue":"17","key":"711_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim J, Hu C, El Achkar CM, Black LE, Douville J, Larson A, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. New Engl J Med. 2019;381(17):1644\u201352.","journal-title":"New Engl J Med."},{"issue":"5454","key":"711_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1126\/science.287.5454.820","volume":"287","author":"T Hermann","year":"2000","unstructured":"Hermann T, Patel DJ. Biochemistry - Adaptive recognition by nucleic acid aptamers. Science. 2000;287(5454):820\u20135.","journal-title":"Science"},{"issue":"6405","key":"711_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.aat5011","volume":"361","author":"GJ Knott","year":"2018","unstructured":"Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866\u20139.","journal-title":"Science"},{"issue":"6","key":"711_CR12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41591-019-0473-8","volume":"25","author":"DP Wolf","year":"2019","unstructured":"Wolf DP, Mitalipov PA, Mitalipov SM. Principles of and strategies for germline gene therapy. Nat Med. 2019;25(6):890\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"711_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"YH Weng","year":"2019","unstructured":"Weng YH, Xiao HH, Zhang JC, Liang XJ, Huang YY. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37(5):801\u201325.","journal-title":"Biotechnol Adv"},{"issue":"7","key":"711_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/d41573-020-00078-0","volume":"19","author":"F Wang","year":"2020","unstructured":"Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020;19(7):441\u20132.","journal-title":"Nat Rev Drug Discov"},{"key":"711_CR15","doi-asserted-by":"crossref","unstructured":"Li HY, Yang Y, Hong WQ, Huang MY, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Tar. 2020;5(1).","DOI":"10.1038\/s41392-019-0089-y"},{"key":"711_CR16","unstructured":"ASGCT. Gene, cell, & RNA therapy landscape report Q3 2024. 2024. https:\/\/www.asgct.org\/publications\/landscape-report. Accessed 28 Dec 2024."},{"key":"711_CR17","unstructured":"Xu L, Shao Z, Fang X, Xin Z, Zhao S, Zhang H, et al. Exploring precision treatments in immune-mediated inflammatory diseases: harnessing the infinite potential of nucleic acid delivery. Explor. n\/a (n\/a):20230165."},{"issue":"10","key":"711_CR18","first-page":"294","volume":"38","author":"CE Keeler","year":"1947","unstructured":"Keeler CE. Gene therapy. J Hered. 1947;38(10):294\u20138.","journal-title":"J Hered"},{"key":"711_CR19","unstructured":"FDA. Vitravene (fomivirsen sodium intravitreal injectable) injection. 2002. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20961_Vitravene.cfm. Accessed 5 Oct 2024."},{"issue":"1","key":"711_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. PNAS. 1978;75(1):285\u20138.","journal-title":"PNAS"},{"issue":"6","key":"711_CR21","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51(6):2529\u201373.","journal-title":"Nucleic Acids Res"},{"key":"711_CR22","unstructured":"Wathion N. Public statement on Vitravene (fomivirsen): withdrawal of the marketing authorisation in the European Union. 2002. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vitravene. Accessed 25 Sep 2024."},{"issue":"1","key":"711_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-020-0164-4","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang W, Sun Q. Novel targeted drugs approved by the NMPA and FDA in 2019. Signal Transduct Tar. 2020;5(1):65.","journal-title":"Signal Transduct Tar"},{"issue":"3","key":"711_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335\u20139.","journal-title":"Drugs"},{"key":"711_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108162","volume":"100","author":"P Ghasemiyeh","year":"2021","unstructured":"Ghasemiyeh P, Mohammadi-Samani S, Firouzabadi N, Dehshahri A, Vazin A. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. Int Immunopharmacol. 2021;100: 108162.","journal-title":"Int Immunopharmacol"},{"key":"711_CR26","doi-asserted-by":"crossref","unstructured":"Ranjbar S, Emamjomeh A, Sharifi F, Zarepour A, Aghaabbasi K, Dehshahri A, et al. Lipid-based delivery systems for flavonoids and flavonolignans: liposomes, nanoemulsions, and solid lipid nanoparticles. Pharmaceutics. 2023;15(7).","DOI":"10.3390\/pharmaceutics15071944"},{"issue":"1","key":"711_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1086\/515085","volume":"28","author":"A Meyerhoff","year":"1999","unstructured":"Meyerhoff A. US Food and Drug Administration approval of Am Bisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28(1):42\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"711_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NR Stone","year":"2016","unstructured":"Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome(\u00ae)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485\u2013500.","journal-title":"Drugs"},{"key":"711_CR29","unstructured":"FDA approves DaunoXome as first-line therapy for Kaposi\u2019s sarcoma. Food and Drug Administration. J Int Assoc Physicians AIDS Care. 1996;2(5):50-1."},{"issue":"1","key":"711_CR30","volume":"2013","author":"J Lao","year":"2013","unstructured":"Lao J, Madani J, Pu\u00e9rtolas T, \u00c1lvarez M, Hern\u00e1ndez A, Pazo-Cid R, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013(1): 456409.","journal-title":"J Drug Deliv"},{"issue":"2","key":"711_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"YC Barenholz","year":"2012","unstructured":"Barenholz YC. Doxil\u00ae\u2014The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334.","journal-title":"J Control Release"},{"key":"711_CR32","unstructured":"FDA. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed 20 Sep 2024."},{"issue":"12","key":"711_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084\u20137.","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"711_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0169-409X(89)90024-0","volume":"3","author":"P Cullis","year":"1989","unstructured":"Cullis P, Mayer L, Bally M, Madden T, Hope M. Generating and loading of liposomal systems for drug-delivery applications. Adv Drug Deliv Rev. 1989;3(3):267\u201382.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"711_CR35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components. Mol Pharm. 2022;19(6):1669\u201386.","journal-title":"Mol Pharm"},{"issue":"15","key":"711_CR36","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","volume":"8","author":"I Hafez","year":"2001","unstructured":"Hafez I, Maurer N, Cullis P. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8(15):1188\u201396.","journal-title":"Gene Ther"},{"issue":"11","key":"711_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci U S A. 2024;121(11): e2307800120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"711_CR38","doi-asserted-by":"publisher","first-page":"2300006","DOI":"10.1002\/anbr.202300006","volume":"3","author":"X Tang","year":"2023","unstructured":"Tang X, Zhang Y, Han X. Ionizable lipid nanoparticles for mRNA delivery. Adv Nanobiomed Res. 2023;3(8):2300006.","journal-title":"Adv Nanobiomed Res."},{"key":"711_CR39","doi-asserted-by":"crossref","unstructured":"Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188.","DOI":"10.1016\/j.addr.2022.114416"},{"issue":"9","key":"711_CR40","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/jbm.a.37705","volume":"112","author":"K Mrksich","year":"2024","unstructured":"Mrksich K, Padilla MS, Joseph RA, Han EL, Kim D, Palanki R, et al. Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length. J Biomed Mater Res A. 2024;112(9):1494\u2013505.","journal-title":"J Biomed Mater Res A"},{"issue":"12","key":"711_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"BL Mui","year":"2013","unstructured":"Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;2(12): e139.","journal-title":"Mol Ther Nucleic Acids."},{"key":"711_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jconrel.2020.06.038","volume":"325","author":"R Mohammadinejad","year":"2020","unstructured":"Mohammadinejad R, Dehshahri A, Madamsetty VS, Zahmatkeshan M, Tavakol S, Makvandi P, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release. 2020;325:249\u201375.","journal-title":"J Control Release"},{"key":"711_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119792","volume":"588","author":"T Suzuki","year":"2020","unstructured":"Suzuki T, Suzuki Y, Hihara T, Kubara K, Kondo K, Hyodo K, et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int J Pharm. 2020;588: 119792.","journal-title":"Int J Pharm"},{"issue":"1","key":"711_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"711_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","volume":"362","author":"J Casper","year":"2023","unstructured":"Casper J, Schenk SH, Parhizkar E, Detampel P, Dehshahri A, Huwyler J. Polyethylenimine (PEI) in gene therapy: current status and clinical applications. J Control Release. 2023;362:667\u201391.","journal-title":"J Control Release"},{"issue":"6","key":"711_CR46","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","volume":"34","author":"R Tenchov","year":"2023","unstructured":"Tenchov R, Sasso JM, Zhou QA. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjug Chem. 2023;34(6):941\u201360.","journal-title":"Bioconjug Chem"},{"key":"711_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495\u2013501.","journal-title":"Drugs"},{"issue":"2","key":"711_CR48","first-page":"20210146","volume":"4","author":"F Zhou","year":"2024","unstructured":"Zhou F, Huang L, Li S, Yang W, Chen F, Cai Z, et al. From structural design to delivery: mRNA therapeutics for cancer immunotherapy. Explor. 2024;4(2):20210146.","journal-title":"Explor"},{"issue":"9","key":"711_CR49","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1021\/jacs.6b12964","volume":"139","author":"CA Sanhueza","year":"2017","unstructured":"Sanhueza CA, Baksh MM, Thuma B, Roy MD, Dutta S, Pr\u00e9ville C, et al. Efficient liver targeting by polyvalent display of a compact ligand for the asialoglycoprotein receptor. J Am Chem Soc. 2017;139(9):3528\u201336.","journal-title":"J Am Chem Soc"},{"key":"711_CR50","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","volume":"203","author":"AA D'Souza","year":"2015","unstructured":"D\u2019Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting\u2014Strategies and applications. J Control Release. 2015;203:126\u201339.","journal-title":"J Control Release"},{"issue":"5","key":"711_CR51","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/cb501028c","volume":"10","author":"S Matsuda","year":"2015","unstructured":"Matsuda S, Keiser K, Nair JK, Charisse K, Manoharan RM, Kretschmer P, et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol. 2015;10(5):1181\u20137.","journal-title":"ACS Chem Biol"},{"issue":"49","key":"711_CR52","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958\u201361.","journal-title":"J Am Chem Soc"},{"key":"711_CR53","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2147\/DDDT.S281631","volume":"16","author":"CN Majeed","year":"2022","unstructured":"Majeed CN, Ma CD, Xiao T, Rudnick S, Bonkovsky HL. Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy. Drug Des Devel Ther. 2022;16:1827\u201345.","journal-title":"Drug Des Devel Ther."},{"issue":"31","key":"711_CR54","doi-asserted-by":"publisher","first-page":"19502","DOI":"10.1074\/jbc.273.31.19502","volume":"273","author":"AR Kolatkar","year":"1998","unstructured":"Kolatkar AR, Leung AK, Isecke R, Brossmer R, Drickamer K, Weis WI. Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain. JBC. 1998;273(31):19502\u20138.","journal-title":"JBC."},{"issue":"6","key":"711_CR55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"711_CR56","doi-asserted-by":"publisher","first-page":"2100108","DOI":"10.1002\/adtp.202100108","volume":"4","author":"T Tieu","year":"2021","unstructured":"Tieu T, Wei Y, Cifuentes-Rius A, Voelcker NH. Overcoming barriers: clinical translation of siRNA nanomedicines. Adv Therap. 2021;4(9):2100108.","journal-title":"Adv Therap."},{"issue":"8","key":"711_CR57","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1073\/pnas.1200718109","volume":"109","author":"JE Zuckerman","year":"2012","unstructured":"Zuckerman JE, Choi CHJ, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. PNAS. 2012;109(8):3137\u201342.","journal-title":"PNAS"},{"key":"711_CR58","first-page":"62","volume":"14","author":"A Dehshahri","year":"2012","unstructured":"Dehshahri A, Oskuee RK, Ramezani M. Plasmid DNA delivery into hepatocytes using a multifunctional nanocarrier based on sugar-conjugated polyethylenimine. Gene Ther Mol Biol. 2012;14:62\u201371.","journal-title":"Gene Ther Mol Biol."},{"key":"711_CR59","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2174\/157341312801784339","volume":"8","author":"A Dehshahri","year":"2012","unstructured":"Dehshahri A, Kazemi Oskuee R, Thomas Shier W, Ramezani M. \u03b2-Galactosylated Alkyl-oligoamine derivatives of polyethylenimine enhanced pDNA delivery into hepatic cells with reduced toxicity. Curr Nanosci. 2012;8:548\u201355.","journal-title":"Curr Nanosci"},{"issue":"7","key":"711_CR60","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/0885328214551010","volume":"29","author":"Z Sabahi","year":"2015","unstructured":"Sabahi Z, Samani SM, Dehshahri A. Conjugation of poly(amidoamine) dendrimers with various acrylates for improved delivery of plasmid encoding interleukin-12 gene. J Biomater Appl. 2015;29(7):941\u201353.","journal-title":"J Biomater Appl"},{"issue":"6","key":"711_CR61","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s11274-004-2238-9","volume":"21","author":"MT Yazdi","year":"2005","unstructured":"Yazdi MT, Ghasemi Y, Ghasemian A, Shokravi S, Niknahad H, Amini M, et al. Bioconversion of hydrocortisone by Cyanobacterium Fischerella ambigua PTCC 1635. World J Microbiol Biotechnol. 2005;21(6):811\u20134.","journal-title":"World J Microbiol Biotechnol"},{"issue":"1","key":"711_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Tar. 2020;5(1):101.","journal-title":"Signal Transduct Tar"},{"issue":"5","key":"711_CR63","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tips.2022.02.003","volume":"43","author":"JM Migliorati","year":"2022","unstructured":"Migliorati JM, Jin J, Zhong X-b. siRNA drug Leqvio (inclisiran) to lower cholesterol. Trends Pharmacol Sci. 2022;43(5):455\u20136.","journal-title":"Trends Pharmacol Sci"},{"issue":"16","key":"711_CR64","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New Engl J Med. 2020;382(16):1507\u201319.","journal-title":"New Engl J Med."},{"issue":"16","key":"711_CR65","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. New Engl J Med. 2020;382(16):1520\u201330.","journal-title":"New Engl J Med."},{"issue":"7","key":"711_CR66","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acs.bioconjchem.3c00205","volume":"34","author":"EA Narasipura","year":"2023","unstructured":"Narasipura EA, VanKeulen-Miller R, Ma Y, Fenton OS. Ongoing clinical trials of nonviral siRNA therapeutics. Bioconjug Chem. 2023;34(7):1177\u201397.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"711_CR67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. New Engl J Med. 2023;389(3):228\u201338.","journal-title":"New Engl J Med."},{"issue":"9","key":"711_CR68","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331(9):740\u20139.","journal-title":"JAMA"},{"issue":"10","key":"711_CR69","first-page":"14","volume":"4","author":"B Roehr","year":"1998","unstructured":"Roehr B. Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care. 1998;4(10):14\u20136.","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"711_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114872","volume":"199","author":"Y Kawamoto","year":"2023","unstructured":"Kawamoto Y, Wu Y, Takahashi Y, Takakura Y. Development of nucleic acid medicines based on chemical technology. Adv Drug Deliv Rev. 2023;199: 114872.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"711_CR71","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/17425247.2023.2251890","volume":"20","author":"S Khan","year":"2023","unstructured":"Khan S, Rehman U, Parveen N, Kumar S, Baboota S, Ali J. siRNA therapeutics: insights, challenges, remedies and future prospects. Expert Opin Drug Deliv. 2023;20(9):1167\u201387.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"711_CR72","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.3390\/ijms24044019","volume":"24","author":"O Ebenezer","year":"2023","unstructured":"Ebenezer O, Comoglio P, Wong GK-S, Tuszynski JA. Development of novel siRNA therapeutics: a review with a focus on inclisiran for the treatment of hypercholesterolemia. Int J Mol Sci. 2023;24(4):4019.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"711_CR73","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549\u201371.","journal-title":"BioDrugs"},{"issue":"3","key":"711_CR74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26(3):708\u201317.","journal-title":"Mol Ther"},{"issue":"3","key":"711_CR75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109\u201318.","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"711_CR76","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","volume":"63","author":"J Fang","year":"2011","unstructured":"Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6656","key":"711_CR77","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda L, Papp TE, Triebwasser MP, Yadegari A, Fedorky MT, Tanaka N, et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science. 2023;381(6656):436\u201343.","journal-title":"Science"},{"key":"711_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"OB Suhr","year":"2015","unstructured":"Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:1\u20139.","journal-title":"Orphanet J Rare Dis"},{"key":"711_CR79","unstructured":"DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides. 2004. https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-8754062-B2. Accessed 29 Oct 2024."},{"key":"711_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2021.715844","volume":"2","author":"MD McSweeney","year":"2021","unstructured":"McSweeney MD, Mohan M, Commins SP, Lai SK. Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy. Front allergy. 2021;2: 715844.","journal-title":"Front allergy."},{"issue":"3","key":"711_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","volume":"122","author":"T Ishida","year":"2007","unstructured":"Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349\u201355.","journal-title":"J Control Release"},{"key":"711_CR82","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"711_CR83","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z, et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022;13(1):5561.","journal-title":"Nat Commun"},{"issue":"2","key":"711_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/pharmaceutics13020159","volume":"13","author":"S Fumoto","year":"2021","unstructured":"Fumoto S, Yamamoto T, Okami K, Maemura Y, Terada C, Yamayoshi A, et al. Understanding in vivo fate of nucleic acid and gene medicines for the rational design of drugs. Pharmaceutics. 2021;13(2):159.","journal-title":"Pharmaceutics"},{"issue":"2","key":"711_CR85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","volume":"24","author":"Y Fang","year":"2017","unstructured":"Fang Y, Xue J, Gao S, Lu A, Yang D, Jiang H, et al. Cleavable PEGylation: a strategy for overcoming the \u201cPEG dilemma\u201d in efficient drug delivery. Drug Deliv. 2017;24(2):22\u201332.","journal-title":"Drug Deliv"},{"key":"711_CR86","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcis.2024.06.158","volume":"674","author":"R M\u00fcnter","year":"2024","unstructured":"M\u00fcnter R, Larsen JB, Andresen TL. The vast majority of nucleic acid-loaded lipid nanoparticles contain cargo. J Colloid Interface Sci. 2024;674:139\u201344.","journal-title":"J Colloid Interface Sci"},{"issue":"5","key":"711_CR87","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s11051-014-2423-1","volume":"16","author":"A Dehshahri","year":"2014","unstructured":"Dehshahri A, Sadeghpour H, Kazemi Oskuee R, Fadaei M, Sabahi Z, Alhashemi SH, et al. Interleukin-12 plasmid DNA delivery using l-thyroxine-conjugated polyethylenimine nanocarriers. J Nanoparticle Res. 2014;16(5):2423.","journal-title":"J Nanoparticle Res."},{"key":"711_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114417","volume":"188","author":"T Nakamura","year":"2022","unstructured":"Nakamura T, Sato Y, Yamada Y, Abd Elwakil MM, Kimura S, Younis MA, et al. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv Drug Deliv Rev. 2022;188: 114417.","journal-title":"Adv Drug Deliv Rev"},{"key":"711_CR89","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","volume":"370","author":"JB Simonsen","year":"2024","unstructured":"Simonsen JB. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies-challenges and opportunities. J Control Release. 2024;370:763\u201372.","journal-title":"J Control Release"},{"issue":"6","key":"711_CR90","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.ymthe.2021.02.015","volume":"29","author":"D Klein","year":"2021","unstructured":"Klein D, Goldberg S, Theile CS, Dambra R, Haskell K, Kuhar E, et al. Centyrin ligands for extrahepatic delivery of siRNA. Mol Ther. 2021;29(6):2053\u201366.","journal-title":"Mol Ther"},{"issue":"14","key":"711_CR91","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1093\/nar\/gkaa595","volume":"48","author":"A Biscans","year":"2020","unstructured":"Biscans A, Caiazzi J, Davis S, McHugh N, Sousa J, Khvorova A. The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy. Nucleic Acids Res. 2020;48(14):7665\u201380.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"711_CR92","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/nar\/gky1239","volume":"47","author":"A Biscans","year":"2019","unstructured":"Biscans A, Coles A, Haraszti R, Echeverria D, Hassler M, Osborn M, et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res. 2019;47(3):1082\u201396.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"711_CR93","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown KM, Nair JK, Janas MM, Anglero-Rodriguez YI, Dang LT, Peng H, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40(10):1500\u20138.","journal-title":"Nat Biotechnol"},{"key":"711_CR94","doi-asserted-by":"crossref","unstructured":"Hariharan VN, Nakamura T, Shin M, Tang Q, Sontakke V, Caiazzi J, et al. Phosphocholine headgroup chemistry alters the extrahepatic accumulation of lipid conjugated siRNA. Mol Ther Nucleic Acids. 2024.","DOI":"10.1016\/j.omtn.2024.102230"},{"issue":"8","key":"711_CR95","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1021\/bc200235q","volume":"22","author":"MR Alam","year":"2011","unstructured":"Alam MR, Ming X, Fisher M, Lackey JG, Rajeev KG, Manoharan M, et al. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem. 2011;22(8):1673\u201381.","journal-title":"Bioconjug Chem"},{"issue":"1a","key":"711_CR96","first-page":"56","volume":"22","author":"T Adamus","year":"2018","unstructured":"Adamus T, Kortylewski M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn). 2018;22(1a):56\u201360.","journal-title":"Contemp Oncol (Pozn)."},{"issue":"1","key":"711_CR97","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18(1):265\u201391.","journal-title":"Nat Protoc"},{"issue":"3","key":"711_CR98","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","volume":"13","author":"R Kedmi","year":"2018","unstructured":"Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, et al. A modular platform for targeted RNAi therapeutics. Nat Nanotechnol. 2018;13(3):214\u20139.","journal-title":"Nat Nanotechnol"},{"key":"711_CR99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Control Release. 2024;372:113\u201340.","journal-title":"J Control Release"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T16:02:14Z","timestamp":1745596934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00711-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"20 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors would like to thank Shiraz University of Medical Sciences. No grant was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mona Mansouri, Kimia Mansouri, Zahra Taheri, Samira Hossaini Alhashemi, and Ali Dehshahri have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Idea for the article: Mona Mansouri, Kimia Mansouri, and Ali Dehshahri; writing\u2014original draft preparation: Mona Mansouri, Kimia Mansouri, Samira Hossaini Alhashemi, and Ali Dehshahri; writing\u2014review and editing: Zahra Taheri and Samira Hossaini Alhashemi. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}